No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
317 |
4. Check minimum number of eventsNone |
317 |
5. Include endpointsNone |
317 |
6. Filter based on genotype QC (FinnGen only) |
317 |
Control definitions (FinnGen only)
- Control exclude
- MYELOPROF
Extra metadata
- First used in FinnGen datafreeze
- DF2, additional
Similar endpoints
↥List of similar endpoints to
Chronic myeloid leukaemia [CML], BCR/ABL-positive
based on the number of shared cases.
Similar with more cases:
- Myeloid leukaemia
- Myeloid leukaemia
- Myeloproliferative diseases
- Primary_lymphoid and hematopoietic malignant neoplasms
- Primary_lymphoid and hematopoietic malignant neoplasms
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2730 | 1222 | 1459 |
| Only index persons | 1748 | 801 | 947 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 61.57 | 61.90 | 61.03 |
| Only index persons | 59.17 | 59.30 | 59.06 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 317 | 144 | 173 |
| Unadjusted period prevalence (%) | 0.06 | 0.05 | 0.08 |
| Median age at first event (years) | 58.29 | 57.54 | 58.92 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 306
- Matched controls
- 3062
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
323.0
304
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
536.0
308.5
271
43
189
Kela drug reimbursment
Imatinib
+∞
214.7
180
*
L01XE01
ATC
[U] imatinib; oral
+∞
182.0
156
*
XW000
NOMESCO Finland
Bone marrow biopsy
85.4
155.7
170
44
9863/3-C42.1
ICD-O-3
Chronic myeloid leukemia, NOS, of bone marrow
+∞
142.0
125
*
L01EA01
ATC
imatinib; oral (bcr-abl tyrosine kinase inhibitors)
+∞
100.7
91
*
L01XX05
ATC
hydroxycarbamide; oral
1166.9
91.7
85
*
316
Kela drug reimbursment
Imatinib
+∞
89.0
81
*
M04AA01
ATC
allopurinol; systemic
12.2
76.6
167
274
152
Kela drug reimbursment
Nilotinib
+∞
66.1
61
*
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
170.7
65.9
67
5
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
112.9
59.5
63
7
150
Kela drug reimbursment
Dasatinib
+∞
51.5
48
*
L01XX28
ATC
[D] imatinib; oral
+∞
48.2
45
*
L01XE06
ATC
[U] dasatinib; systemic
+∞
46.0
43
*
L01XE08
ATC
[U] nilotinib; oral
+∞
43.8
41
*
C91.1
ICD-10 Finland
Chronic lymphocytic leukaemia of B-cell type
39.2
35.2
44
13
328
Kela drug reimbursment
Nilotinib
+∞
34.0
32
*
L01EA03
ATC
nilotinib; oral
+∞
32.9
31
*
127
Kela drug reimbursment
Transplant complication
24.2
31.1
44
21
324
Kela drug reimbursment
Dasatinib
+∞
27.5
26
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.1
25.6
92
238
L03AA02
ATC
filgrastim; parenteral
11.8
24.6
46
45
212
Kela drug reimbursment
Gout
14.1
24.4
42
34
L01EA02
ATC
dasatinib; oral
+∞
22.1
21
*
R50.9
ICD-10 Finland
Fever, unspecified
4.4
20.8
86
251
C91.0
ICD-10 Finland
Acute lymphoblastic leukaemia [ALL]
+∞
20.0
19
*
WW500
NOMESCO Finland
Blood transfusion
9.8
19.1
39
45
C95.0
ICD-10 Finland
Acute leukaemia of unspecified cell type
+∞
18.9
18
*
C92.9
ICD-10 Finland
Myeloid leukaemia, unspecified
+∞
18.9
18
*
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
201.8
18.7
19
*
A05AA02
ATC
ursodeoxycholic acid; oral
13.7
18.1
31
25
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.4
17.9
49
89
9875/3-C42.1
ICD-O-3
Chronic myelogenous leukemia, BCR/ABL positive of bone marrow
+∞
17.9
17
*
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
190.5
17.7
18
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
25.9
17.6
24
10
D72.9
ICD-10 Finland
Disorder of white blood cells, unspecified
95.3
16.7
18
*
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
179.3
16.7
17
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
11.4
16.6
31
30
121
Kela drug reimbursment
Severe hypofunction of sexual glands
15.7
16.2
26
18
170
Kela drug reimbursment
Bosutinib
+∞
15.8
15
*
L03AB05
ATC
interferon alfa-2b; parenteral
+∞
15.8
15
*
L04AA01
ATC
[U] ciclosporin; systemic
17.2
15.5
24
15
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
14.9
175
1026
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
35.8
13.6
17
5
C95.9
ICD-10 Finland
Leukaemia, unspecified
+∞
13.6
13
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.8
13.6
62
192
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
42.1
13.3
16
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
7.0
13.0
32
50
C03CA01
ATC
furosemide; systemic
2.6
12.7
120
607
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
135.3
12.5
13
*
B25.8
ICD-10 Finland
Other cytomegaloviral diseases
135.3
12.5
13
*
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
+∞
11.5
11
*
L01XE14
ATC
[U] bosutinib; oral
+∞
11.5
11
*
WW200
NOMESCO Finland
Immunization
6.7
11.2
28
45
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
45.0
11.0
13
*
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
62.2
10.7
12
*
R72
ICD-10 Finland
Abnormality of white blood cells, not elsewhere classified
113.7
10.5
11
*
360
Kela drug reimbursment
Bosutinib
+∞
10.5
10
*
L03AA04
ATC
NA
+∞
10.5
10
*
Y84
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
16.8
10.5
16
10
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
5.1
10.3
32
68
L04AD01
ATC
ciclosporin; systemic
9.6
10.2
20
22
B73
ICPC
Leukaemia
56.8
9.7
11
*
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
103.1
9.5
10
*
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
+∞
9.4
9
*
2051A
ICD-9 Finland
Myeloid leukaemia, Chronic
+∞
9.4
9
*
J05AB11
ATC
valaciclovir; oral
2.9
9.4
60
235
B03XA01
ATC
erythropoietin; parenteral
16.2
9.1
14
9
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.0
8.7
34
92
J02AC03
ATC
voriconazole; systemic
92.5
8.5
9
*
B03XA02
ATC
darbepoetin alfa; parenteral
7.4
8.4
19
27
WW409
NOMESCO Finland
Other aferesis
+∞
8.4
8
*
L01EA04
ATC
bosutinib; oral
+∞
8.4
8
*
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
+∞
8.4
8
*
A01AB04
ATC
amphotericin B; local oral
4.3
8.1
29
72
C82.1
ICD-10 Finland
Follicular lymphoma grade II
22.7
8.1
11
5
9823/3-C42.1
ICD-O-3
B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma of bone marrow
22.7
8.1
11
5
J05AB01
ATC
aciclovir; systemic
2.3
7.8
79
399
L01BB02
ATC
mercaptopurine; oral
15.5
7.8
12
8
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.0
7.8
45
166
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
46.2
7.8
9
*
J01MA14
ATC
moxifloxacin; systemic
3.1
7.6
42
147
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.2
7.5
86
457
A04AA01
ATC
ondansetron; systemic, rectal
3.6
7.4
32
95
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
7.3
7
*
373
Kela drug reimbursment
Ponatinib
+∞
7.3
7
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.4
7.3
65
307
A41.9
ICD-10 Finland
Sepsis, unspecified
5.2
7.1
21
43
H02AB09
ATC
hydrocortisone; systemic
7.4
6.8
15
21
C91.9
ICD-10 Finland
Lymphoid leukaemia, unspecified
41.0
6.8
8
*
H02AB06
ATC
prednisolone; systemic
1.9
6.8
146
991
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
4.3
6.8
24
60
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.3
6.6
67
336
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.8
6.5
42
166
D75.2
ICD-10 Finland
Essential thrombocytosis
71.3
6.4
7
*
D64.9
ICD-10 Finland
Anaemia, unspecified
2.7
6.4
44
180
C92.7
ICD-10 Finland
Other myeloid leukaemia
+∞
6.3
6
*
C92.2
ICD-10 Finland
Atypical chronic myeloid leukaemia, BCR/ABL- negative
+∞
6.3
6
*
C91.2
ICD-10 Finland
Subacute lymphocytic leukemia
+∞
6.3
6
*
L01XE24
ATC
[U] ponatinib; oral
+∞
6.3
6
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.3
6.1
58
284
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
145
213
11.70
103.95
4.5
2.8
68.4
68.3
e9/l
0.01
110
165
89
0
+∞
98.14
15.7
0.0
—
—
—
0
0
87
0
+∞
95.80
11.7
0.0
—
—
—
0
0
183
697
4.85
43.20
6.6
2.7
339.5
8174.3
umol/l
3.52
175
596
265
1492
5.73
34.28
29.2
9.2
3.6
4.1
e9/l
2.81
255
1310
42
50
9.53
33.40
10.0
6.6
181.1
117.3
iu/ml
—
10
7
59
117
5.97
29.56
1.8
1.8
1.3
1.5
g/l
1.02
52
101
35
44
8.82
26.53
1.1
1.3
138.3
89.3
u/ml
—
9
8
230
1297
3.82
26.31
15.0
6.8
1.2
1.2
mmol/l
0.33
203
1098
41
71
6.48
23.39
1.7
1.6
—
—
—
0
0
19
11
18.31
23.08
1.8
1.5
—
—
—
0
0
31
41
8.27
22.48
6.6
3.9
53.2
57.4
%
0.75
31
41
209
1185
3.24
22.09
13.5
5.8
1.2
1.2
mmol/l
0.28
201
1068
28
34
8.94
21.72
2.2
2.0
33.6
33.1
pg
0.26
28
34
28
39
7.78
19.39
6.5
3.7
3.0
4.6
e9/l
2.33
28
39
20
18
11.79
19.06
4.1
3.4
—
—
—
0
0
95
374
3.20
18.47
3.2
2.3
22.8
22.4
%
0.09
83
321
35
66
5.84
18.23
2.5
1.8
—
—
—
0
0
35
66
5.84
18.23
2.3
1.8
—
—
—
0
0
20
25
8.47
15.05
1.1
1.1
—
—
—
0
0
21
28
7.96
15.01
8.3
2.8
46.8
59.5
%
1.05
13
19
20
26
8.14
14.58
4.1
2.0
726.7
555.1
e6/l
—
7
11
148
826
2.49
14.00
3.3
2.5
58.2
56.6
u/l
0.24
143
759
27
53
5.48
13.41
1.1
1.2
—
—
—
0
0
224
1536
2.56
13.13
8.4
4.6
6.7
6.7
mmol/l
0.01
218
1442
122
638
2.48
13.12
2.8
2.0
2.8
3.1
mg/l
0.65
112
545
170
1039
2.37
12.79
4.3
2.6
263.9
149.0
ug/l
2.56
165
951
90
419
2.60
12.26
2.8
2.0
—
—
—
0
0
25
50
5.34
12.16
1.1
1.2
352.1
261.7
u/ml
0.52
19
30
25
51
5.24
11.89
2.5
1.9
—
—
—
0
0
23
49
4.98
10.41
1.8
1.8
—
—
—
0
0
20
40
5.27
9.70
1.6
1.8
—
—
—
0
0
49
188
2.90
9.55
1.8
1.5
—
—
—
0
0
149
943
2.09
9.39
4.3
3.2
—
—
—
0
0
66
300
2.52
9.23
2.5
2.0
—
—
—
0
0
66
301
2.51
9.16
2.5
1.9
—
—
—
0
0
13
18
7.49
8.91
1.0
1.1
—
—
—
0
0
30
89
3.62
8.87
2.4
2.9
—
—
—
0
0
17
32
5.56
8.78
2.6
1.9
—
—
—
0
0
27
75
3.84
8.76
1.7
1.3
—
—
—
0
0
15
26
6.01
8.41
2.8
1.9
—
—
—
0
0
15
26
6.01
8.41
2.8
1.9
—
—
—
0
0
15
26
6.01
8.41
2.8
1.9
—
—
—
0
0
173
1193
1.99
8.26
8.2
4.0
—
—
—
0
0
19
42
4.75
8.23
2.0
1.9
—
—
—
0
0
17
35
5.08
7.98
2.6
1.8
—
—
—
0
0
134
858
1.97
7.81
6.6
3.3
39.9
33.8
u/l
0.42
128
819
25
72
3.68
7.71
1.4
1.2
—
—
—
0
0
32
109
3.15
7.64
2.6
1.9
1.9
4.8
ug/l
0.51
32
99
14
26
5.59
7.31
1.6
1.7
—
—
—
0
0
130
848
1.90
6.99
6.8
3.3
2.3
2.4
mmol/l
2.31
124
743
93
544
2.00
6.87
1.9
1.7
1.6
1.3
mg/l
0.44
76
412
16
36
4.63
6.78
1.9
2.0
—
—
—
0
0
10
14
7.34
6.73
1.8
2.6
—
—
—
0
0
12
21
5.90
6.63
1.0
1.0
—
—
—
0
0
13
25
5.38
6.54
3.2
2.2
—
—
—
0
0
11
18
6.29
6.47
1.6
1.7
—
—
—
0
0
11
18
6.29
6.47
1.6
1.7
—
—
—
0
0
14
32
4.53
5.82
1.9
1.8
—
—
—
0
0
12
24
5.16
5.79
1.8
1.3
20620.5
44514.2
e6/l
—
6
16
57
297
2.12
5.68
9.5
7.2
12.2
12.0
kpa
0.12
52
286
12
25
4.95
5.54
1.5
1.3
377.1
264.9
u/l
0.26
12
25
15
38
4.09
5.50
2.0
1.9
—
—
—
0
0
101
649
1.82
5.44
1.9
1.6
19.6
20.7
nmol/l
0.35
92
552
85
518
1.88
5.42
1.8
1.7
1246.0
1183.8
nmol/l
0.25
79
383
56
300
2.05
5.17
9.6
7.2
1.1
1.1
mmol/l
0.01
39
246
37
172
2.30
4.85
3.7
2.9
0.3
1.5
mmol/l
0.87
25
125
146
1074
1.67
4.71
2.3
2.0
92.6
95.9
pmol/l
0.34
101
556
93
614
1.73
4.45
6.0
2.3
—
—
—
0
0
34
160
2.26
4.34
1.9
1.8
—
—
—
0
0
7
6
11.89
4.29
1.0
1.0
—
—
—
0
0
18
64
2.92
4.03
1.9
1.4
—
—
—
0
0
9
15
6.14
3.84
3.6
1.9
—
—
—
0
0
9
15
6.14
3.84
3.6
1.9
—
—
—
0
0
9
15
6.14
3.84
3.6
1.9
—
—
—
0
0
9
15
6.14
3.84
3.6
1.9
—
—
—
0
0
24
103
2.44
3.77
1.4
2.9
8.4
10.3
g/l
1.82
16
93
8
12
6.81
3.69
3.7
2.1
—
—
—
0
0
8
12
6.81
3.69
3.7
2.1
—
—
—
0
0
16
56
2.96
3.68
1.8
2.4
129.4
129.6
g/l
—
10
40
24
105
2.39
3.62
1.5
2.8
3.3
3.2
g/l
0.19
15
86
136
1031
1.56
3.62
3.8
3.7
24.6
41.0
ng/l
1.89
111
740
227
1933
1.61
3.59
6.1
4.1
14.0
12.2
mm/h
1.07
220
1760
43
240
1.92
3.53
5.5
3.8
2.5
2.0
mmol/l
0.25
35
192
8
13
6.28
3.52
3.6
2.0
—
—
—
0
0
25
113
2.32
3.52
1.5
2.7
7.1
7.4
g/l
0.30
15
89
25
113
2.32
3.52
1.5
2.7
—
—
—
0
0
25
113
2.32
3.52
1.5
2.7
3.6
3.8
g/l
0.28
15
85
8
14
5.83
3.36
1.3
1.4
—
—
—
0
0
8
14
5.83
3.36
1.3
1.4
—
—
—
0
0
32
165
2.04
3.28
1.7
1.5
—
—
—
0
0
6
7
8.71
3.27
1.7
1.3
—
—
—
0
0
21
91
2.40
3.25
1.4
4.3
—
2.8
—
0
9
7
11
6.48
3.20
7.6
1.4
—
—
—
0
0
71
476
1.63
3.12
4.2
3.0
2.4
2.5
mmol/l
0.08
71
423
21
93
2.35
3.10
3.6
2.0
—
—
—
0
0
7
13
5.48
2.88
1.4
1.2
—
—
—
0
0
11
36
3.13
2.83
1.1
1.3
—
—
—
0
0
23
111
2.16
2.80
4.4
3.1
24.3
24.6
mmol/l
0.15
23
106
7
14
5.09
2.74
1.3
1.4
—
—
—
0
0
7
14
5.09
2.74
1.3
1.4
—
—
—
0
0
6
10
6.09
2.71
1.0
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
73
2.40
2.70
2.9
2.1
0.3
0.4
u/ml
0.08
12
35
53
343
1.65
2.66
13.8
6.7
104.0
103.9
mmol/l
0.07
53
331
17
74
2.37
2.63
2.3
1.5
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
7
7.23
2.56
1.2
1.0
109.0
147.1
%
—
5
7
69
485
1.54
2.46
6.0
3.6
133.1
165.7
ng/l
0.13
59
383
19
90
2.18
2.44
2.3
1.8
—
—
—
0
0
11
41
2.74
2.30
1.2
1.1
—
—
—
0
0
97
741
1.45
2.29
4.6
3.1
0.6
0.5
e6/l
0.09
85
548
8
24
3.39
2.19
1.1
3.0
—
—
—
0
0
6
14
4.35
2.16
1.7
1.9
991.7
996.3
u/ml
—
6
14
12
49
2.51
2.13
1.3
1.4
—
—
—
0
0
12
49
2.51
2.13
1.3
1.4
—
—
—
0
0
19
96
2.04
2.10
1.4
1.8
—
144.0
—
0
5
212
1872
1.40
2.09
4.1
3.7
15.1
14.8
pmol/l
0.62
204
1673
5
10
5.06
2.08
17.4
3.8
189.6
201.1
u/l
—
5
10
11
46
2.44
1.87
1.4
2.1
59331.6
5247.2
u/l
—
5
18
5
12
4.21
1.83
3.4
1.2
—
—
—
0
0
11
47
2.39
1.79
1.2
1.5
—
—
—
0
0
59
430
1.46
1.76
4.7
2.8
2.3
1.8
e6/l
0.20
39
234
7
25
2.84
1.66
1.0
1.8
—
—
—
0
0
148
1266
1.32
1.64
3.7
3.8
0.0
0.0
estimate
0.00
25
231
15
77
2.00
1.62
1.3
1.4
—
—
—
0
0
31
201
1.60
1.58
4.2
2.9
57.2
62.8
ml/min/173m2
0.53
21
87
145
1250
1.29
1.47
4.8
5.1
0.0
0.0
estimate
0.00
30
237
12
59
2.07
1.45
1.7
1.4
—
—
—
0
0
6
22
2.76
1.44
1.0
1.2
—
—
—
0
0
13
67
1.98
1.40
1.3
1.4
—
—
—
0
0
9
41
2.23
1.38
1.3
1.5
—
—
—
0
0
6
23
2.64
1.37
1.0
1.0
—
—
—
0
0
9
42
2.18
1.35
1.3
1.5
—
—
—
0
0
9
42
2.18
1.35
1.3
1.5
—
—
—
0
0
9
42
2.18
1.35
1.3
1.5
—
—
—
0
0
9
42
2.18
1.35
1.3
1.5
—
—
—
0
0
9
43
2.12
1.31
1.3
1.5
—
—
—
0
0
70
556
1.33
1.27
3.9
3.9
1.0
1.0
kg/l
2.18
13
78
272
2575
1.40
1.27
36.8
14.4
19.8
24.3
mg/l
1.51
249
2030
229
2116
1.30
1.26
47.7
17.7
14.7
13.7
%
16.46
229
2076
169
1512
1.25
1.19
2.7
2.8
—
—
—
0
0
6
26
2.33
1.19
1.7
1.3
—
—
—
0
0
6
26
2.33
1.19
1.7
1.2
—
—
—
0
0
142
1247
1.25
1.17
3.7
3.7
0.0
0.0
estimate
0.00
28
241
5
20
2.52
1.15
2.2
1.7
0.3
0.2
nmol/l
—
5
14
5
23
2.19
0.98
1.2
3.2
19.6
64.3
u/ml
—
5
23
19
126
1.54
0.93
1.2
1.3
—
—
—
0
0
11
63
1.77
0.91
2.8
1.7
174.9
248.9
pmol/l
1.69
11
57
81
688
1.24
0.88
4.1
4.0
0.0
0.0
estimate
0.00
25
232
34
258
1.36
0.86
4.1
3.4
—
—
—
0
0
13
83
1.59
0.76
1.2
1.2
—
—
—
0
0
12
75
1.62
0.76
2.2
1.6
—
—
—
0
0
5
24
2.10
0.75
1.0
1.1
—
—
—
0
0
14
92
1.55
0.73
2.5
3.3
4.0
4.0
mmol/l
0.03
14
81
13
84
1.57
0.73
1.2
1.2
—
—
—
0
0
55
459
1.24
0.71
3.9
2.6
1.5
1.0
e6/l
0.63
37
260
39
313
1.28
0.69
10.7
7.2
—
—
—
0
0
49
586
0.81
0.68
2.5
3.1
0.7
0.8
ug/l
0.28
31
385
240
2291
1.20
0.67
5.1
4.6
1.9
1.9
mu/l
0.26
231
2068
110
988
1.17
0.66
3.9
3.9
—
—
—
0
0
64
548
1.21
0.65
1.5
1.8
501.1
12780704.5
pmol/l
0.50
51
446
5
30
1.68
0.61
1.0
2.1
15.2
17.0
ug/l
—
5
30
5
30
1.68
0.61
1.0
1.3
—
—
—
0
0
41
339
1.24
0.58
22.8
23.0
1.3
1.3
inr
—
6
43
0
23
0.00
0.58
0.0
1.6
—
—
—
0
0
0
23
0.00
0.58
0.0
1.2
—
—
—
0
0
277
2839
0.81
0.57
54.9
21.0
4.0
4.5
e12/l
25.09
272
2754
8
55
1.47
0.56
1.4
1.4
—
—
—
0
0
8
125
0.63
0.55
1.0
1.0
—
—
—
0
0
253
2440
1.18
0.55
5.0
4.0
1.6
1.3
mmol/l
1.51
244
2228
48
418
1.17
0.43
1.2
1.3
1.3
14.3
u/ml
2.56
17
159
16
206
0.76
0.43
1.8
1.7
—
—
—
0
0
72
795
0.88
0.41
3.6
4.3
23.8
21.7
%
0.53
37
378
5
35
1.44
0.39
1.2
1.2
—
—
—
0
0
5
37
1.36
0.37
2.8
3.9
—
—
—
0
0
6
41
1.47
0.36
1.2
1.6
—
—
—
0
0
49
445
1.12
0.26
1.2
1.3
17.1
37.8
iu/ml
2.24
16
147
15
123
1.23
0.26
1.6
2.9
29.3
70.9
u/ml
0.67
15
118
73
680
1.10
0.25
1.7
1.6
2.1
1.4
mmol/l
1.09
65
570
179
1731
1.08
0.25
3.4
3.2
61.7
50.3
u/l
0.64
169
1614
5
38
1.32
0.23
1.4
1.2
—
1.1
—
0
9
7
93
0.75
0.22
2.3
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
9.1
—
0
13
0
14
0.00
0.20
0.0
2.5
—
—
—
0
0
0
14
0.00
0.20
0.0
2.5
—
—
—
0
0
247
2428
1.08
0.19
31.9
13.7
74.2
79.8
ml/min/173m2
3.20
228
2000
7
60
1.17
0.18
1.1
1.2
—
1.1
—
0
5
16
184
0.86
0.17
1.4
1.9
—
—
—
0
0
35
322
1.10
0.16
1.5
1.9
1.4
1.5
%
0.62
28
290
8
71
1.13
0.16
2.0
1.9
—
—
—
0
0
10
83
1.21
0.15
2.0
2.8
—
—
—
0
0
18
200
0.89
0.13
1.5
2.1
—
—
—
0
0
255
2526
1.05
0.09
5.4
4.5
4.3
4.6
mmol/l
4.84
250
2332
6
56
1.07
0.08
1.0
1.3
—
46.6
—
0
6
5
63
0.79
0.08
1.0
1.2
—
—
—
0
0
7
66
1.06
0.08
1.1
1.2
—
—
—
0
0
241
2393
1.03
0.05
6.3
6.0
39.1
40.3
mmol/mol
1.67
229
2220
253
2515
1.03
0.05
5.2
4.4
1.3
1.5
mmol/l
6.69
246
2313
257
2583
0.97
0.04
5.7
5.0
2.5
2.7
mmol/l
4.92
249
2372
229
2304
0.98
0.04
38.5
15.3
37.0
40.1
%
4.84
152
1654
53
540
0.98
0.02
1.2
1.2
1.0
1.4
u/ml
—
9
147
41
401
1.03
0.02
1.7
1.4
—
—
—
0
0
99
999
0.99
0.01
4.2
4.9
7.5
2.6
ug/l
0.40
91
882
248
2487
0.99
0.01
5.4
4.7
6.1
6.0
mmol/l
0.95
234
2264
16
154
1.04
0.00
1.2
1.3
30.7
152.5
iu/ml
—
6
55
30
302
0.99
0.00
1.6
1.4
—
—
—
0
0
5
56
0.89
0.00
1.2
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
1350.8
—
0
6
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
59
1.02
0.00
1.2
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
5
53
0.94
0.00
1.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
7
70
1.00
0.00
1.1
1.3
—
8.4
—
0
13
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CML and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CML | 4.426 [3.35, 5.85] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.636 |
During the follow-up period (1.1.1998 — 31.12.2019), 322 out of 808 females with CML died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CML | 3.628 [2.8, 4.71] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 423 out of 944 males with CML died.
Mortality risk
Mortality risk for people of age
years, who have CML.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.525% | 0.565% |
| 5 | 2.993% | 4.051% |
| 10 | 7.101% | 9.458% |
| 15 | 13.164% | 18.283% |
| 20 | 22.051% | 29.576% |
Relationships between endpoints
↥Index endpoint: CML – Chronic myeloid leukaemia [CML], BCR/ABL-positive
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data